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Abstract
Background: Subclinical hypothyroidism (SH) is defined as serum levels of thyroid-stimulating hormone (TSH)
above the upper limit with normal concentrations of free T4 (fT4). Its management remains challenging. The aim of
the study was to evaluate clinical and laboratory findings as well as the clinical course of children with SH followed
in a third level hospital. Sixty-five patients aged between 2 and 18 years old were retrospectively studied.
Methods: The patients were followed for a median period of 9 months (range 6 months to 24 months). Those who
normalized TSH levels were discharged (Group 1). If TSH persisted mildly elevated (5-10μUI/mL) with normal fT4
and negative TPOAb/TgAb, they were classified as Group 2 and followed semi-annually without treatment. Those
patients whose TSH raised ≥10μUI/mL or who maintained TSH 5-10μUI/mL and positive TPOAb/TgAb were
considered suitable for thyroxin therapy (Group 3, G3).
Results: In 89% of our patients, TSH concentrations spontaneously reverted to normality or remained stable
without treatment (Groups 1 and 2), whereas less than 11% progressed to clinical hypothyroidism (Group 3).
Baseline TSH was significantly lower in group 1 than in group 3. In group 3 the prevalence of female sex (71%) was
higher and TPO antibodies were present in 85% of patients. The risk of developing overt hypothyroidism in patients
with positive anti-thyroid antibodies respect to those who normalized TSH was 45 (95%CI 6.5–312.5).
Conclusion: Baseline TSH, female sex and the presence of thyroid autoimmunity were the best predictors of the
evolution to SH over time.
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Background
Subclinical hypothyroidism (SH), also known as isolated
hyperthyrotropinemia, is defined as serum thyroid-
stimulating hormone (TSH) concentrations above the
upper limit of the reference range and normal concen-
trations of free T4 (fT4). This situation occurs in less
than 3% of children and adolescents [1, 2], but it is a
cause of concern for parents and primary care physicians
and represents a frequent cause of referral to a pediatric
endocrinologist.
TSH normal range (0.4–0.5μUI/mL to 4.0–5.0μUI/
mL) depends on the method used, with large variations
found between different TSH assays. Idiopathic SH is
characterized by mild elevations of TSH concentrations
levels (5-10μUI/mL) with peripheral hormones fT4 and
triiodothyronine within normal ranges, absence of
thyroid autoimmunity or other conditions that may
account for the increase in TSH, such as certain medica-
tions or genetic disorders (Down syndrome, Pseudohy-
poparathyroidism and others), and without clinical signs
or symptoms of thyroid failure.
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The natural course of idiopathic SH is unclear. Most
patients normalize TSH values and a small percentage
progresses to overt hypothyroidism [3–7]. The risk of
progression to overt hypothyroidism depends on the
cause of SH with high risk in autoimmune forms. There
is a lack of conclusive studies that determine whether
these children with SH might benefit from levothyroxine
treatment [7–9].
On the other hand, adverse health outcomes of SH in
childhood remain controversial. Although it might not
produce adverse effects on growing and development
processes [5, 8, 10], it has been recently associated with
overweight/obesity and metabolic abnormalities [11, 12].
Nevertheless, prospective studies that determine those
deleterious effects are lacking.
This study aimed to analyze the characteristics and
natural evolution of a cohort of children with SH
referred to a third level hospital.
Methods
We analyzed retrospectively patients who were diagnosed
with SH and referred to the Endocrinology Unit of our
hospital between 2014 and 2018. SH was defined as TSH
concentration mildly elevated (5-10μUI/mL) with fT4
within the normal reference range (0.7–1.48 ng/dL). Pa-
tients were assessed at the time of diagnosis, at month 3
and every 6months during follow-up if necessary.
Patients
Inclusion criteria were as follows: patients referred for SH
aged 2 to 18 years old with at least two analytical records:
one at the time of diagnosis and another one during the
follow-up. Patients under 2-years-old and who received
pharmacological treatment that could alter the TSH con-
centrations (anticonvulsants, antipsychotics, glucocorti-
coids, iodine or iodine-rich diet) were excluded. We also
excluded patients with genetic syndromes or under an
acute disease. All patients resided in an area by the Medi-
terranean Sea in an iodine-sufficient population.
All patients had a complete clinical record, physical
examination including anthropometric characteristics
(height, weight), and thyroid exploration at the time of
diagnosis and during follow-up visits. We calculated
body mass index (BMI) and represented the results as
standard deviation (SD) according to age and sex. Obes-
ity was considered if the BMI-SD was above 2 for the
reference population. Short stature was considered if the
height-SD was below 2 for the reference population.
Thyroid function test consisted of TSH, fT4 and
thyroid autoantibodies (anti-peroxidase (TPOAb) and
antithyroglobulin (TgAb)). If necessary –p.e. with
palpable goiter, persisted elevated TSH or positive auto-
immunity–, a thyroid ultrasound was made to assess
thyroid size and echogenicity.
All patients had an initial TSH concentration mildly ele-
vated (5-10μUI/mL) with fT4 within the normal reference
range. The patients were followed for a median period of
9months (range 6–24months). Those patients who nor-
malized TSH levels at the follow-up were discharged
(Group 1, G1); follow-up median period 6months (range
3–9months) whereas those who persisted with elevated
TSH were followed. If TSH persisted mildly elevated (5-
10μUI/mL) with normal fT4 and negative TPOAb/TgAb,
they were classified as Group 2 (G2) and followed semi-
annually without treatment, follow-up median period 12
months (range 9–24months). Those patients whose TSH
raised ≥10μUI/mL or who maintained TSH 5-10μUI/mL
and positive TPOAb/TgAb (regardless fT4 levels) were
considered overt hypothyroidism and suitable for thyroxin
replacement therapy due to hypothyroidism/thyroiditis
(Group 3, G3), follow-up median period 12months (range
9–24months).
Biochemical and hormonal determinations
Blood samples were drawn at 8 a.m. after an overnight
fast. Samples were centrifuged and sera kept frozen at −
20 °C until analysis. Analysis of serum TSH was
performed with CLIA with the aid of an Abbott ARCHI-
TECT instrument (Abbott Diagnostics Division). Total
coefficient of variation (CV) was < 3.3%, functional sensi-
tivity was 0.0038μUI/mL; reference range [99% confidence
interval (CI)]: 0.35–4.94μUI/mL; fT4 was measured by
Abbott ARCHITECT instrument (Abbott Diagnostics
Division; total CV was < 7%, sensitivity of the assay was <
0.4 ng/dL; reference range (99% CI): 0.70–1.48 ng/dL
(conversion factor ng/dL *12.87 = pmol/L). TPOAb were
measured by an Abbott ARCHITECT instrument (Abbott
Diagnostics Division). Total CV was < 7.6%, sensitivity of
the assay was 0.16 IU/mL; reference range: < 5.61 IU/mL.
Statistical analyses
The normality of the evaluated variables was established
using the Kolmogorov-Smirnov test. Quantitative
variables are presented as mean ± SD or as median
(interquartile range: 25th–75th percentile) whereas
qualitative variables are expressed as percentages. Differ-
ences among groups were assessed by the ANOVA or
the non-parametric Kruskal Wallis test. To determine
differences between groups, the Student’s T test or non-
parametric Mann-Whitney U test was used, and to
compare variables at baseline and at follow-up, we used
the Wilcoxon test. Differences in proportions were
analyzed by the χ2 test or Ficher’s exact test. All tests
were two-tailed and a p value < 0.05 was considered sta-
tistically significant. Statistical analyses were performed
using the SPSS package 12.0 and MedCalc Software
12.7.0 (Acacialaan 22, B-8400 Ostend, Belgium).
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The relative risk was calculated as the ratio of the pro-
portions of cases having a positive antibodies in the G3
group (6 out of 7), respect to group G1 (0 out of 44). This
test was performed with the aid of MedCalc Statistical
Software version 19.1.7 (MedCalc Software Ltd., Ostend,
Belgium; https://www.medcalc.org; 2020) The program
calculates the relative risk with 95% confidence interval,
the z-statistic and associated P-value. If P is less than 0.05,
it can be concluded that the proportions are significantly
different in the two groups, and there is an increased risk
in one group compared to the other.
The study was approved by the Ethics Committee. All
patients or legal surrogates gave informed consent prior
to participation.
Results
The study included 65 patients diagnosed with SH (51%
female). The median age at diagnosis was 7.75 (4.4–9.17)
years old. Clinical and laboratory findings at the time of
diagnosis are shown in Table 1. The main reason for the
study of thyroid function was routine analytical (41,5%,
n: 27), obesity (13,8%, n: 9), short stature (12.3%, n: 8),
asthenia (10.7%, n: 7) or others (18.4%, n: 14).
Regarding clinical characteristics, the medians of weight,
height and BMI were within the normal ranges (− 0.39SD,
− 0.47SD and − 0.5SD respectively) with 13.8% of obesity
and 12,3% of patients with short stature. No patient had
goiter on physical examination.
There was a family history of thyroid disease in 8 cases
(12.3%).
At the time of diagnosis, all patients were asymptom-
atic of thyroid dysfunction, and these patients were
observed without treatment.
Table 2 shows the clinical and laboratory characteris-
tics of patients classified into 3 different groups accord-
ing to evolution. TSH concentrations returned to
normal ranges in 44 patients (67.6%) (G1), 14 patients
(21.5%) maintained slightly elevated TSH concentrations
with negative thyroid antibodies (G2) and 7 patients
(10.7%) had TSH ≥10μUI/mL or TSH 5-10μUI/mL and
positive TPOAb/TgAb (6 patients) (G3).
The prevalence of females was higher in the G3 (71%),
but in the other two groups, the distribution was similar
(50% in G1 and 57% G2). Regarding the age as well as a
family history of autoimmune diseases, no differences
were found among the 3 groups.
Mean baseline TSH concentrations differed among the
3 groups (p = 0.012), significant differences were found
in TSH values between G1 and G3 (F = 4.768; p = 0.016)
whereas no differences were found between G1 and G2
or between G2 and G3. No differences were found in
fT4 concentrations at baseline among the 3 groups (F =
3.083; p = 0.053) (Fig. 1). The percentage change of TSH
at follow-up with respect to baseline was 47.8% decrease
in group 1, a 6.9% decrease in group 2 and a 24.7% in-
crease in group 3 (Table 2).
BMI evolution was evaluated during the study and no
significant difference was found in obesity (BMI-SD > 2)
prevalence during follow-up in all patients (13,8 to
10.7%). In terms of height there were no differences.
Thyroid autoimmunity was observed in 85% of pa-
tients of G3 and none of G1 and G2 (p > 0.001). The risk
of developing overt hypothyroidism in patients with
positive anti-thyroid antibodies with respect to those
who normalized TSH was 45 (95%CI 6.5–312.5).
Of all the patients, 35,3% underwent a thyroid ultra-
sound and a structure suggestive of thyroiditis (heteroge-
neous, hypoechoic and in some cases enlarged
ultrasound pattern) was found in 6 patients, all in the
G3. There was 1 patient with nodules on ultrasound
without other significant findings; the rest of the patients
presented a normal ultrasound.
Discussion
In general terms, SH seems to affect less than 3% of the
child population and usually displays a natural course
towards the maintenance or spontaneous resolution in
Table 1 Anthropometrical, clinical and laboratory characteristics
at baseline
n: 65
Female (%) 33 (51%)
Age (years) 7.75 (4.4–9.17)
Referral for analytic study:
Routine 27 (41.5%)
Obesity 9 (13.8%)




BMI-SD −0.5 [(−1.09)-(+ 0.86)]
Weight-SD −0.39 [− 0.99)-(+ 1.2)]
Height-SD − 0.47 [(− 1.38)-(+ 0.75)]
Obesity (BMI-SD ≥2) 9 (13.8%)
Short stature (<2SD) 8 (12.3%)
Goiter 0
Familiar history (Autoimmune disease) 8 (12.3%)
Laboratory results:
TSH (μUI/mL) 6.7 (6.1–7.8)
Free thyroxin (ng/dL) 1.1 (1.0–1.3)
TPO positivity 6 (9.2%)
US performed (%) 23 (35,3%)
Data are expressed as median (IQR) or percentage (%)
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Table 2 Clinical and laboratory characteristics among groups
Group 1 Group 2 Group 3 Significance
N 44 (67,6%) 14 (21,5%) 7 (10,7%)
Female 51.2% 42.9% 71.4% N.S.
Age at baseline (years) 6.7 (4.0–9.2) 8.17 (6.48–9.48) 8.17 (7.4–9.17) N.S.
Familiar History (Autoimmune disease) 11.4% 7.1% 14.3% N.S.
TSH (μUI/mL) at baseline 6.6 (6.02–7.35)a 7.05 (6.07–8.12) 8.2 (6.7–9.4) 0.012
Free thyroxin (ng/dL) at baseline 1.15(1.02–1.3) 1.0(0.95–1.3) 1.0(0.88–1.1) 0.03
TSH (μUI/mL) at follow-up 3.7(2.94–4.27)b, c 6.1(5.17–8.0)d 1.0(088–1.1) < 0.001
Free thyroxin (ng/dL) at follow-up 1.07 (0.98–1.2) 1.04(0.9–1.19) 0.88 (0.83–1.1) N.S.
Percentage change in TSH (baseline vs follow up) −47.8
((−35.3)-(− 56.7))b,c
−6.9 ((−17.3)-1.9)d 24.7 (14.6–95.5) < 0.001
BMI-SD −0.61 [(−1.1)-0.83] 0.21 [(− 0.62)-1.18] 0.43[(− 0.68) − 0.85] NS
Obesity (BMI ≥2 SD) 6 (13,6%) 3 (21,4%) 0 (0%) N.S.
Height-SD -0.85 [(− 0.98)-0.67] −0.45 [(2.27)-0.82] 0.35 [(−2.2)-1.4] N.S.
Height-SD <2SD 1 (2,2%) 5 (35,7%) 2 (28,5%) N.S.
TPOAb/TgAb positivity 0 (0%) 0 (0%) 6 (85%) 0.001
Performed US 10 (22%) 6 (42%) 7 (100%)
Tiroiditis by US 0 (0%) 1 (16%) 6 (83%) 0.04
N.S.: non significant
a: p < 0.016group 1 vs group 3
b: p < 0.001 group 1 vs group 2
c p < 0.001 group 1 vs group 3
d: p < 0.001 group 2 vs group 3
Quantitative variables are expressed as median (IQ range p25-p75)
Qualitative variables are expressed as N (%)
Fig. 1 TSH values at baseline and follow-up. Patients were classified into three groups according TSH levels at the end of the follow up. Group 1
(G1): TSH ≤5μUI/mL (n: 44); Group 2 (G2): TSH 5-10μUI/mL, normal fT4 and negative TPOAb/TgAb (n: 14); Group 3 (G3): suitable for thyroxin
therapy due to TSH ≥10μUI/mL or TSH 5-10μUI/mL and positive TPOAb/TgAb (n: 7)
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variable time in most cases (68–88%) and only a few
cases progress to overt hypothyroidism or autoimmune
thyroiditis. There are few studies to date that evaluate
SH and its evolution in childhood [5, 10, 13, 14]. In our
study, most of the patients either normalized their TSH
levels or maintained their TSH levels under subclinical
range values (89%). Only a small percentage presented
overt hypothyroidism or autoimmune thyroiditis and
needed treatment (11%). These data are similar to those
of a 2-year prospective study presented by Wasniewska
et al., in which 88% of patients normalized o preserved
their TSH levels and 12% developed hypothyroidism [5].
In an attempt to anticipate events, Lazar et al. found
that predictive factors for sustained abnormal TSH levels
were initial TSH > 7.5μUI/mL and female gender [1]. Re-
cently, Gammons et al. concluded that a TSH >8μUI/
mL would be the cut-off point to refer to a pediatric
endocrinologist for evaluation and management [15]. Al-
though, because of the small number of patients, an
AUC could not be assessed to determine the cutoff level
of TSH that predicts evolution towards hypothyroidism,
in our cohort baseline TSH levels of G3 were signifi-
cantly higher.
Regarding the weight, in our study, no significant
changes were detected between obesity prevalence at
baseline and during follow-up in all the patients, and the
BMI-SD did not worsen during follow-up in any patient.
However, in the G2 group, those who persisted with a
TSH 5-10μUI/mL had a higher prevalence of obesity,
which would suggest that it may have a role in increas-
ing TSH levels. It is thought that the mildly elevated
TSH is the consequence of obesity rather than the cause,
as an attempt to increase energy expenditure, with an
improvement of the thyroid function parameters when
lowering the BMI, as has been mentioned on multiples
studies [16–21]. Contrary to what one would expect,
none of the patients with obesity belonged to the G3
with overt hypothyroidism.
It is known that autoimmunity is a key factor that de-
termines the major progression to hypothyroidism. In
our study, almost all patients in G3 met this condition
and 71.4% were women, which is a distribution that
already occurs in most autoimmune diseases. Our results
are in agreement with Wasnieska et al. [22] who studied
the long term evolution of a large cohort of girls with
subclinical hypothyroidism and found that underlying
Hashimoto thyroiditis was the main factor to become
overtly hypothyroid or require L-T4 treatment. In fact, it
has been reported that in children with Hashimoto thy-
roiditis the evolution of thyroid status is frequently char-
acterized by a spontaneous worsening over time, even in
the cases who initially present with a mild biochemical
picture [23]. Lazarus et al. analyzed the results of 7 ob-
servational studies and showed that elevated TgAb and
TPOAb at diagnosis were associated with an increased
risk of progression in some but not all studies [7].
Treatment with levothyroxine was initiated in all pa-
tients who presented TSH ≥10μUI/mL or TSH 5-10μUI/
mL and positive TPOAb/TgAb (G3). The dilemma arises
in deciding whether patients with maintained mildly
elevated TSH (G2) should be treated or not with
levothyroxine and what benefits it can bring against pos-
sible consequences of SH, since good-quality studies
examining the effect of treatment of SH in children are
lacking [9, 24–26]. In our case, no patients were treated
since none presented associated symptoms or alterations
that could be related to it.
The current study has its limitations. For instance, it is
a retrospective study with a small number of patients,
and genetic causes such as alterations in the TSH recep-
tor that could explain mildly elevated TSH have not
been investigated. On the other hand, the possible im-
pact on growth and intellectual development has not
been assessed in this study.
Conclusion
Although SH in childhood is a frequent issue and a mat-
ter of concern between primary care pediatrics, it seems
to be a benign and remitting condition; based on our re-
sults and in comparison, with the literature, expectant
behavior is the best option, always individualizing each
patient. Perhaps repeating a second determination by
the primary care pediatrician of TSH and fT4 in 1–3
months and if alteration persists refer to specialist many
cases could be resolved and, therefore, save time and
resources.
However, in the case of pediatric SH, prospective stud-
ies are lacking to determine a sensitive and specific level
of TSH to predict the progression to hypothyroidism. It
is important to determine if it is a process with negative
or positive autoimmunity, since on this latter case, the
probability of progression to hypothyroidism is greater.
As seen in the current study, baseline TSH, female sex
and the presence of thyroid autoimmunity were the best
predictors of the evolution to SH over time.
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